Lu-177-PNT6555

Lutetium-177 PNT6555 · POINT Biopharma (a wholly owned subsidiary of Eli Lilly and Company)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Lu-177-PNT6555, covering 2025-06-25 to 2025-06-25. Get the full timeline:

Most recent: Clinical Trial Update: FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) [Phase 1]

See pricing